Craig Hallum Increases Cellebrite DI (NASDAQ:CLBT) Price Target to $16.00

Cellebrite DI (NASDAQ:CLBTGet Free Report) had its target price lifted by equities research analysts at Craig Hallum from $14.00 to $16.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target would suggest a potential upside of 47.74% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. William Blair upgraded Cellebrite DI from a “market perform” rating to an “outperform” rating in a research report on Wednesday, March 13th. Needham & Company LLC boosted their target price on Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Finally, Bank of America upped their price objective on Cellebrite DI from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $12.30.

View Our Latest Report on Cellebrite DI

Cellebrite DI Stock Down 1.6 %

CLBT stock opened at $10.83 on Monday. The company has a market cap of $2.22 billion, a P/E ratio of -25.19, a PEG ratio of 1.95 and a beta of 1.54. Cellebrite DI has a twelve month low of $5.22 and a twelve month high of $12.50. The business has a fifty day moving average of $10.83 and a 200-day moving average of $8.91.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $93.01 million during the quarter, compared to the consensus estimate of $85.43 million. Cellebrite DI had a positive return on equity of 173.14% and a negative net margin of 24.94%. As a group, equities research analysts anticipate that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brasada Capital Management LP increased its holdings in Cellebrite DI by 125.1% in the third quarter. Brasada Capital Management LP now owns 375,332 shares of the company’s stock valued at $2,762,000 after purchasing an additional 208,566 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new position in Cellebrite DI in the third quarter valued at about $50,270,000. Swiss National Bank grew its stake in Cellebrite DI by 30.7% in the third quarter. Swiss National Bank now owns 107,800 shares of the company’s stock valued at $825,000 after acquiring an additional 25,300 shares during the period. New York State Common Retirement Fund grew its stake in Cellebrite DI by 166.0% in the third quarter. New York State Common Retirement Fund now owns 15,440 shares of the company’s stock valued at $118,000 after acquiring an additional 9,635 shares during the period. Finally, Meitav Investment House Ltd. acquired a new position in Cellebrite DI in the third quarter valued at about $2,399,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

See Also

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.